Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

PharmAust Reports Phase IIb Clinical Trial in Pet Dogs with B Cell Lymphoma Identifies Therapeutic Window for Monepantel

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce that interim analysis of its Phase IIb trial has provided further supportive evidence of the monepantel blood plasma levels required to suppress B cell lymphoma growth in pet owners’ dogs.

PharmAust is now in a good position to further optimize treatment levels of MPL to facilitate a Phase III study. Monepantel in this stage of the study indicated no material adverse events.

PharmAust’s Chief Scientific Officer Dr. Richard Mollard stated, “As per the previous high-dose trial using monepantel tablets, a range of drug blood plasma levels was again observed in this lower dose trial, but this time all within a narrower spread. Examination of the blood plasma data in the context of the previous trial, while referencing side effects and efficacy, has reinforced our understanding of a target therapeutic window for monepantel’s use in dogs with B cell lymphoma. The Phase IIb trial will continue to increase recruitment numbers to gain sufficient information for a future Phase III registration trial.”

PharmAust’s Chairman, Dr Roger Aston stated, “This represents a material advance in optimizing the treatment regimen for canine patients with B-Cell lymphoma and may have applicability to other anticancer treatments in companion animals and in humans. Cancer therapy is all about optimizing efficacy and minimizing adverse events and this is particularly important with aggressive late-stage cancers such a Stage 4/5 B-Cell lymphoma. Following a Phase III trial PharmAust will also examine how monepantel can be integrated into the current standard of care.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine